These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 38715825)
1. Comparative metabolomics of MCF-7 and MCF-7/TAMR identifies potential metabolic pathways in tamoxifen resistant breast cancer cells. Mishra A; Srivastava A; Srivastava A; Sharma LK; Mishra AK; Shrivastava A Am J Transl Res; 2024; 16(4):1337-1352. PubMed ID: 38715825 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362 [TBL] [Abstract][Full Text] [Related]
4. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Lykkesfeldt AE; Madsen MW; Briand P Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264 [TBL] [Abstract][Full Text] [Related]
5. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Madsen MW; Reiter BE; Lykkesfeldt AE Mol Cell Endocrinol; 1995 Apr; 109(2):197-207. PubMed ID: 7664983 [TBL] [Abstract][Full Text] [Related]
6. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
7. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro. Xiong H; Jin X; You C Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994 [TBL] [Abstract][Full Text] [Related]
8. Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Kim S; Lee J; Oh SJ; Nam SJ; Lee JE Oncol Rep; 2015 Sep; 34(3):1613-9. PubMed ID: 26166014 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells. Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390 [TBL] [Abstract][Full Text] [Related]
10. IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells. Vaziri-Gohar A; Zheng Y; Houston KD Mol Cancer Res; 2017 Apr; 15(4):489-497. PubMed ID: 28096479 [TBL] [Abstract][Full Text] [Related]
11. Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells. Choi MC; Kim SK; Choi YJ; Choi YJ; Kim S; Jegal KH; Lim SC; Kang KW Arch Pharm Res; 2023 Dec; 46(11-12):907-923. PubMed ID: 38048029 [TBL] [Abstract][Full Text] [Related]
12. Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. Walter W; Thomalla J; Bruhn J; Fagan DH; Zehowski C; Yee D; Skildum A Springerplus; 2015; 4():689. PubMed ID: 26576332 [TBL] [Abstract][Full Text] [Related]
13. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Ryu CS; Kwak HC; Lee JY; Oh SJ; Phuong NT; Kang KW; Kim SK Biochem Pharmacol; 2013 Jan; 85(2):197-206. PubMed ID: 23123664 [TBL] [Abstract][Full Text] [Related]
15. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069 [TBL] [Abstract][Full Text] [Related]
16. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929 [TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer. Lee J; Kim EA; Kang J; Chae YS; Park HY; Kang B; Lee SJ; Lee IH; Park JY; Park NJ; Jung JH BMC Mol Cell Biol; 2024 Apr; 25(1):12. PubMed ID: 38649821 [TBL] [Abstract][Full Text] [Related]
18. FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. Pellegrino M; Rizza P; Donà A; Nigro A; Ricci E; Fiorillo M; Perrotta I; Lanzino M; Giordano C; Bonofiglio D; Bruno R; Sotgia F; Lisanti MP; Sisci D; Morelli C Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769419 [No Abstract] [Full Text] [Related]
19. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709 [TBL] [Abstract][Full Text] [Related]
20. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells. Liu X; Miao W; Huang M; Li L; Dai X; Wang Y Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]